Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.
You may also be interested in...
J&J/Omrix’s Evicel Wins CHMP Recommendation
Human fibrogen/thrombin product would be indicated for supportive treatment in surgery.
J&J/Omrix’s Evicel Wins CHMP Recommendation
Human fibrogen/thrombin product would be indicated for supportive treatment in surgery.
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.